Podcasts about Teva

At Lupine Creative, Kate Wolff serves as pack leader on all business. An award-winning advertising executive, Kate has stewarded some of the world's most impactful brands, helping them tap into popular culture. She built a traditional 360 advertising background through work at agencies including Publicis Modem, DDB, TBWAChiatDay, Omelet LA and RQ. Kate's deep understanding of the advertising and marketing space frequently turns traditional brand marketing strategy on its head through cultural, data and behavioral insights. She built LA-based agency Lupine Creative in February 2020 with a base of experiential, social, and cultural expertise to boast year-over-year revenue growth. The approach that's made the difference: spark solutions with cultural strategy and then create through experiences and partnerships that manifest as cultural capital. Lupine clients include Spotify, Max, LG, Google, Teva, FX, BoxLunch and more.The team has an impressive events innovation story: in their first three months of existence, they created HBO Max's first-ever, award-winning virtual Pride celebration, resulting in a continuous partnership. Kate and her team also champion a diversity story; she is a co-founder of Do the WeRQ, a movement to increase queer creativity, representation, and share-of-voice across the industry. Further extending her commitment to innovative and sustainable solutions, Kate is Co-Founder of LumiTerra. Her dedication to environmental sustainability supported the creation of the LumiCup, an aluminum-based product line designed to reduce the reliance on single-use plastics dramatically.

Send us Fan MailIn this lesson, Rabbi Yisroel Bernath explores one of the deepest ideas in Kabbalah: Atzmut, the Absolute Essence of Hashem. After learning about Mimaleh, the Divine energy that fills the world, Sovev, the Divine energy that transcends the world, and Ratzon and Ta'anug, will and delight, this class goes deeper still.What is beyond nature? What is beyond miracles? What is beyond what we understand, feel, or experience? Kabbalah teaches that Hashem is not only found when the sea splits. He is also found when the heart beats, the lungs breathe, the body works, and an ordinary day quietly becomes a gift.This lesson helps us stop waiting for dramatic inspiration and begin recognizing Hashem in real life: in mitzvahs, gratitude, prayer, relationships, patience, and the small choices that turn the world into a home for G-d. Based on the attached Atzmut chapter.Key Takeaways1. Nature is G-d hidden in a pattern: Teva is not the absence of Hashem. It is Hashem concealed inside the steady rhythm of creation.2. Miracles are G-d breaking the pattern: Nissim reveal that Hashem is not limited by nature, systems, habits, or expectations.3. Atzmut is beyond both nature and miracles: Hashem is not defined by hiddenness or revelation. He can be found in both, because He transcends both.4. The greatest miracles are often the ones we stop noticing: Breathing, waking up, walking, healing, functioning, these are not “ordinary.” They are constant gifts.5. Faith must move from makif to pnimi: It is not enough for faith to hover around us as inspiration. It has to enter our thoughts, speech, and actions.6. Atzmus is revealed in simple mitzvahs: The highest Divine Essence is not only found in mystical experiences. It is revealed in lighting candles, giving tzedakah, putting on tefillin, saying a bracha, and choosing kindness.7. Don't wait to feel spiritual before living spiritually: The beinoni may not control every feeling, but can choose thought, speech, and action.8. The goal is Dirah B'Tachtonim: Hashem wants a home here, in this world, in this body, in this relationship, in this moment, even before the coffee fully kicks in.#KabbalahForEveryone #Atzmut #chassidus #ChabadChassidus #JewishWisdom #PracticalKabbalah #NatureAndMiracles #Teva #Nissim #DivineEssence  #spiritualgrowth #JewishSpirituality #TorahForLife #InnerWork Available now:Paperback: https://www.amazon.com/Forgiveness-Experiment-What-Would-Your/dp/1069217638Kindle: https://www.amazon.com/dp/B0FR2QNJL6Audiobook: https://bit.ly/4tPFZhVSupport the showGot your own question for Rabbi Bernath? He can be reached at rabbi@jewishndg.com or http://www.theloverabbi.comSingle? You can make a profile on www.JMontreal.com and Rabbi Bernath will help you find that special someone.Donate and support Rabbi Bernath's work http://www.jewishndg.com/donateFollow Rabbi Bernath's YouTube Channel https://www.youtube.com/user/ybernathAccess Rabbi Bernath's Articles on Relationships https://medium.com/@loverabbi

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Biogen has made a significant acquisition by purchasing Apellis Pharmaceuticals, a move expected to boost its 2026 revenue guidance with promising growth prospects. This strategic acquisition, along with strong sales from new drugs, enhances Biogen's position in the competitive market for neurological disorders. By integrating Apellis' offerings, Biogen is poised to strengthen its portfolio, particularly in areas of unmet medical need. On the regulatory front, AbbVie has achieved a milestone with its drug Rinvoq (upadacitinib), which has received dual approvals from the European Union for treating non-segmental vitiligo and severe alopecia areata. These approvals were based on successful Phase 3 data, underscoring Rinvoq's efficacy as a JAK inhibitor in tackling autoimmune conditions. This development not only highlights AbbVie's commitment to expanding its therapeutic portfolio but also positions upadacitinib as a potential mainstay treatment for dermatological autoimmune diseases. AstraZeneca Pharma India has secured approval from the Central Drugs Standard Control Organization for Enhertu (trastuzumab deruxtecan) in the neoadjuvant setting for HER2-positive early breast cancer. This approval marks a significant advancement in personalized cancer therapy, offering new hope for patients with this aggressive form of breast cancer. In terms of industry collaborations, the landscape is witnessing numerous partnerships and strategic alliances that are driving innovation forward. Skyverna Therapeutics and ElevateBio have entered a five-year clinical and commercial supply agreement for autoimmune CAR-T therapy, reflecting the growing interest in cell therapies for rare diseases. Meanwhile, Vertex Pharmaceuticals and AbCellera have joined forces to accelerate drug discovery in autoimmune T-cell engagement, supported by a $28 million upfront investment. These collaborations emphasize the importance of combining expertise and resources to advance complex therapeutic solutions. The integration of artificial intelligence in drug development continues to gain momentum. Evinova and Merck KGaA's strategic collaboration aims to leverage AI and machine learning to enhance clinical trials' efficiency, potentially ushering in a new era of precision medicine. Such partnerships highlight the transformative potential of AI in streamlining research and development processes. In funding news, Core Biomedicine has secured $21 million in Series A financing to advance its precision oncology therapeutics. Enlivex's substantial $400 million private placement aims at advancing prediction markets treasury and Allocetra immunotherapy, further accentuating the focus on personalized medicine targeting specific cancer pathways. Clinical trials have also delivered promising results. ProMIS Neurosciences reported positive interim safety and biomarker data from its Phase 1b study of PMN310 for Alzheimer's disease. This monoclonal antibody targets amyloid-beta oligomers implicated in Alzheimer's pathology, offering hope for patients with this debilitating disorder. Mergers and acquisitions remain active, exemplified by Caldera Therapeutics' reverse merger with Synlogic alongside $278 million in financing to advance its bispecific antibody for inflammatory bowel disease. This move reflects a broader trend toward consolidating resources to tackle complex autoimmune conditions. Eli Lilly's ascent to the top of Norstella's pipeline-to-patient productivity index is noteworthy, driven by successful launch strategies and rapid development cycles. This achievement underscores Eli Lilly's effective alignment of R&D efforts with market needs, particularly in areas such as GLP-1 receptor agonists that have transformed diabetes care. Teva Pharmaceuticals is demonstrating resilience through its innovative medicines portfolio amidst declining generic sales. The unexpected surge in Ajovy sales highlights Teva's pivot toward high-value branded drugs amidst competitive pressures. Novo Nordisk faces legal challenges as it navigates allegations regarding Cagrisema's Phase 3 study protocol changes. Legal scrutiny around transparency in clinical trial disclosures continues to highlight the importance of ethical practices and investor trust. Collectively, these developments illustrate a vibrant yet challenging environment where scientific advancements in immunotherapy and targeted treatments intersect with strategic business alignments focused on sustainable growth. As these trends unfold, they promise more effective treatments for complex diseases while companies adapt to an evolving market environment demanding agility and foresight. As always, stay tuned to Pharma Daily for more insights into how these transformations continue to shape the future trajectory of drug development and healthcare delivery globally.Support the show

Welcome to the Daily Compliance News. Each day, Tom Fox, the Voice of Compliance, brings you compliance-related stories to start your day. Sit back, enjoy a cup of morning coffee, and listen in to the Daily Compliance News. All from the Compliance Podcast Network. Each day, we consider four stories from the business world, compliance, ethics, risk management, leadership, or general interest for the compliance professional. Top AI stories include: Defense lawyers claim DOJ FCPA case is a ‘Milli Vanilli' offering.  (Law360) sub req'd eBay and execs agree to pay $55.7 MM in settlement for harassment. (Law360) sub req'd Teva can't whine about agreed-to admissions. (Law360) sub req'd 1st Circuit skeptical that hiring SW is a lie detector. (Law360) sub req'd To learn about the intersection of Sherlock Holmes and the modern compliance professional, check out Tom's latest book, The Game is Afoot-What Sherlock Holmes Teaches About Risk, Ethics and Investigations on Amazon.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Could the Federal Reserve's next move be a rate hike? Renaissance Macro Head of Economics Neil Dutta joins Squawk on the Street to make the case. Plus, Mondelez CEO Dirk Van de Put discusses better-than-expected earnings, consumer demand, and what's driving growth for the maker of Oreo. And Teva CEO Richard Francis breaks down the company's raised full-year outlook, the latest quarterly results, and what's ahead for its drug pipeline. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Some big news here at Engearment. Our most prolific writer, Erin Trail is branching off to create her own gear review company called Trail Dispatch. We are stoked for her and her next steps! We had 46 meetings last week at OMA to learn about gear for Spring 2027 (hard to even think that far ahead LOL!) We met with all the companies you love. We have a few videos up on the Engearment YouTube channel from Kuat, EXPED, Smartwool, Merrell, Fjallraven, Peak Design, RTIC, Kelty, BOA, Teva, and more. New gear from Nocs Provision (Zero Tube) Gregory (Terros 25 and Alpaca gear storage). Thermarest quilt, KUHL Escape tote. I am going on a media trip to Idaho in a few weeks with a small group of other media folks to test gear from Gregory, MSR, Thermarest, and several other awesome outdoor gear companies. I am stoked!        

Liturgické čítania na každý deň z rímskokatolíckeho liturgického kalendára. Návšteva preblahoslavenej Panny Márie (sviatok) Sof 3, 14-18 (Ch) Iz 12, 2-3. 4b-d. 5-6 R.: Plesajme a jasajme, lebo uprostred nás je Svätý, Boh. Lk 1, 39-56 Tento podcast vám prinášajú študenti, členovia tímu a priatelia Kolégia Antona Neuwirtha. Email: podcast@kolegium.org

Smo sredi prvega letošnjega vročinskega vala, ki kar ne pojenja. Po Evropi padajo temperaturni rekordni, število smrti povezanih z vročino se povečuje. V tokratnem Studiu ob 17tih preverjamo, kakšno je stanje pri nas. Kako se zavarovati pred vročino, kako je potrebno poskrbeti za delavce, za živali in kako se pravilno ohladiti, da to ne bi ogrozilo vašega zdravja.

Avui et servim una sessi

David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com  David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

TEVA Shoe Review

Today's podcast is a natural follow up to our podcasts on Slow Codes and Unilateral DNR orders.Today we talk about a new study about how clinicians talk about potentially non-beneficial life-prolonging treatments, published in JAMA Network Open. Do they adhere to society guidelines, which allow as permissible approaches only shared decision-making and following institutional policy.  Or do they take alternative approaches, like not offering interventions, not mentioning interventions, or simply stating a plan to limit interventions? Turns out doctors are using these alternative approaches frequently. Our guests are Jason Batten, Liz Dzeng, and Teva Brender, all clinicians, all of whom have been thinking about and wrestling with the ethical reasoning behind these approaches. We all admit to using these approaches.  Are the alternative approaches wicked games (song hint), and our response should be to stop these behaviors, beginning with ourselves? After all, if you ask patients or surrogates, they're likely to say they want all the options and may not universally welcome recommendations.  Or, as with slow codes, does the fact that these alternative approaches are in common use suggest that the guidelines should be revised?  You listen and decide! -Alex Smith   Additional links: Dzeng 2023 JAMA IM: The larger ethnographic study from which data was drawn with data drawn from high- medium- and low-intensity hospitals. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2806959 Brender 2025 JAMA NO: Factors that exacerbate or mitigate moral distress related to potentially non-beneficial treatments.https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835316 Dzeng 2015 JAMA IM: Study illustrating that more senior physicians feel more comfortable not offering or recommending against futile CPR. Relevant quote: "Experienced physicians at all sites generally were comfortable engaging in best interest decision making and, when clinically appropriate, not offering or making explicit recommendations against offering resuscitation." https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2212265 Weiss Goitiandia AJOB 2025: Reasons why some clinicians would hesitate to go to the ethics committee / futility process for these discussions: https://www.tandfonline.com/doi/10.1080/15265161.2025.2457734?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Axelrod AJOB 2025: Discusses some of the systemic consequences of using physiologic futility as a standard and how it might contribute to a healthcare system that imposes aggressive treatments on vulnerable patients. https://www.tandfonline.com/doi/full/10.1080/15265161.2025.2530715#d1e152  

“When your patient is your priority—getting them safe, highly pure, quality medicine—you're aligned with the health agency. That alignment and engagement really help.”Manda Pasarkar, Global Head of Regulatory Affairs CMC at Sanofi, has spent over 20 years mastering the intersection of chemistry and compliance—a rare combination that positions her at the forefront of pharmaceutical regulatory strategy.Pasarkar progressed from scientist roles at Teva through regulatory positions at Bayer, and now leads regulatory strategy for Sanofi's multi-billion dollar portfolio across biologics and small molecules, securing numerous drug marketing approvals in the US, EU, Japan, and China. She's also a Distinguished Toastmaster (DTM)—a designation fewer than 1% of Toastmasters International members achieve.In a recent PharmaSource podcast episode, Manda shared insights on navigating complex global regulatory landscapes, building productive agency relationships, leveraging ICH guidelines, working with CDMOs, and preparing for AI's impact on regulatory CMC.Read more.

In this episode of the Arete Executive Podcast, Richard Triggs sits down with Teva Smith, communications strategist, content creator and fractional communications consultant, to explore the power of creativity, personal brand and human connection in a world overloaded with digital noise. Teva's career has moved across countries, industries and creative disciplines. From growing up in South Africa and spending almost a decade in the UK, to building a strong professional background in pharmaceutical PR, marketing and independent education, her path has been anything but linear. Today, she brings together more than 20 years of communications experience with a bold, funny and highly human online presence that has opened new professional doors. Richard and Teva discuss the rise of fractional work, why more businesses are looking for senior expertise without the risk or cost of a full-time hire, and how experienced professionals can bring value quickly across different organisations, projects and industries. They also explore the growing need for executives and business leaders to develop a more compelling online presence, not just as a polished career summary, but as a genuine expression of who they are. The conversation then moves into Teva's own creative journey. She shares how making videos started as a personal outlet, why humour and vulnerability have helped her content resonate, and how authenticity, when handled with integrity, can become a serious professional advantage. This is a conversation about more than social media. It is about courage, creativity, reputation, reinvention and the importance of staying human in business. For leaders, executives and aspiring C-suite professionals, Teva offers a clear reminder: people do not just connect with credentials. They connect with personality, story and trust. Key Timestamps 1:46 - Teva's work across fractional communications, content creation and creative projects 2:16 - The rise of fractional work and why businesses are using senior expertise differently 6:07 - Teva's journey from South Africa to Australia, the UK and back to Brisbane 8:00 - Creativity, storytelling and human connection as the thread through Teva's career 10:09 - How Teva started creating online videos and developed her distinctive voice 13:04 - Balancing professional reputation with personal expression online 20:24 - How leaders and business owners can start building a stronger personal brand 34:58 - Teva's final message on bravery, creativity and having more fun in business USEFUL LINKS: Teva Smith on LinkedIn Teva Smith's Website Richard Triggs on LinkedIn SUBSCRIBE HERE: Apple Podcast | Stitcher | Subscribe on Android | Player.fm | RSS | Spotify

Hi ha gent que es pensa que quan et trenquen el cor el que et cal

The Engearment Team has been up to a lot this year, and I want to shine a light on new additions, fun coverage, reviews, and upcoming events! Devan welcomes her son Luke to the world! Nikita Bagg joins the team from Canada! Ryan Humphries goes to Zion with Teva. Erin Trail tackles the Ragnar race. Andrew Piotrowski does the Boston Marathon! Upcoming Outside Music Festival. Secret Patagonia and KUHL projects. Helly Hansen 3.5 layer WPB?!? Benchmade new chef's knife. EXPED Ultra Line

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of significant advancements, strategic investments, and regulatory updates reshaping the landscape of drug development and patient care. In a remarkable move, Novartis has announced a $23 billion investment in the U.S., with plans to establish an Active Pharmaceutical Ingredient facility in Morrisville, North Carolina. This venture aims to bolster Novartis' manufacturing capabilities for solid dose tablets, capsules, and RNA therapeutics, marking a critical investment in U.S. pharmaceutical manufacturing. This decision reflects a broader trend of pharmaceutical giants strengthening their domestic production capacities to enhance supply chain resilience and support local economies. Eli Lilly has introduced Foundayo, its oral GLP-1 drug for obesity. Despite not matching the initial sales figures of Novo Nordisk's Wegovy pill, Lilly remains optimistic about capturing a substantial share of the obesity treatment market. The launch highlights the increasing competition and interest in GLP-1 therapies, recognized for their effectiveness in managing weight and metabolic disorders. This growing focus on obesity treatment underscores the industry's commitment to addressing one of today's most pressing public health challenges. As Eli Lilly navigates competitive obesity treatment landscapes amidst significant revenue growth tempered by falling drug prices, it highlights industry-wide trends focusing on metabolic disorders as lucrative therapeutic opportunities while balancing financial performances against strategic pivots and regulatory changes. Turning to respiratory diseases, Merck's portfolio tells two different stories. Winrevair for Pulmonary Arterial Hypertension is on a growth trajectory, while Ohtuvayre for Chronic Obstructive Pulmonary Disease has seen a decline in sales. This contrast illustrates the dynamic nature of therapeutic adoption and market demand within respiratory care, reminding us of the constant evolution within disease treatment markets. AstraZeneca is navigating complex regulatory landscapes with its approach to the U.S. "Most Favored Nation" drug pricing policy by excluding certain reference markets in its forecasts. This strategy highlights the challenges pharmaceutical companies face in adapting to policies aimed at controlling drug prices while maintaining market viability. In immunology, AbbVie is defending its leading drug Skyrizi against new competitors like Johnson & Johnson's Icotyde for plaque psoriasis. Skyrizi's impressive 30.9% sales growth in early 2026 showcases AbbVie's robust market position and strategic focus on immunology—a field that continues to see intense innovation and competition. Regeneron has faced setbacks with Eylea due to regulatory delays, causing quarterly sales to dip below $1 billion for the first time since 2018. This situation underscores the critical impact regulatory environments can have on revenue generation and highlights the need for strategic agility within pharma companies. Teva Pharmaceuticals is experiencing a successful transformation under CEO Richard Francis, driven by its innovative portfolio including Austedo, Uzedy, and Ajovy. This shift from generics to branded pharmaceuticals marks Teva's commitment to innovation and sustainable growth. In oncology collaboration news, Bristol Myers Squibb has ended its partnership with Zymeworks on a Phase 1 cancer bispecific antibody project from Celgene. This decision emphasizes the complexities of biotech collaborations and the necessity for strategic alignment in advancing cancer treatment pipelines. Unfortunately, not all news is positive. GSK and Alector have halted a Phase 2 trial of their Alzheimer's candidate after interim analysis showed it was unlikely to meet primaSupport the show

What does the surge in memory stocks signal about the broader AI trade? A look at those moves, ahead of four Mag 7 earnings reports tonight. Then early SpaceX and xAI investor Peter Diamandis on Elon Musk's lawsuit against OpenAI. Plus, how to value a SpaceX IPO. And the CEO of Teva Pharma after reporting an earnings beat and announcing its first acquisition in a decade. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A viral AI video posted by Donald Trump depicts the president being baptized in blood while uttering what appears to be a magical incantation - "Ashaka shan la.” Perhaps the video was shared on TruthSocial and then removed like the controversy over a white robed Trump as the Tarot Magician. If he did not post the video, then it still serves the purpose of undermining the truth of what it implies. In some African languages and Sanskrit the phrase translates to “drinking the bitterness” or “drinking hope.” If you reverse the text, it reads "Al nahs akasha,” meaning "misfortune," "bad luck," or a "sinister influence." In traditional Arabic astrology, Saturn is known as al-nahs al-akbar (the greater misfortune). The phrase literally translates as "Akasha brings bad luck." The video was reportedly posted, or faked, on April 18-19 weekend, the unofficial start of Beltane, and coincides with both UFO Disclosure narratives being pushed with the Book of Enoch to undermine the New Testament, and the supposed Federal approval of of psychedelic ibogaine compounds. In the case of Enoch, which is largely metaphoric, it is being used alongside of the America Reads the Bible event put on by Israel — the goal is to justify holy war with the Old Testament while desecrating the New Testament. In the case of ibogaine, it is manufactured by PsyRx, an Israeli company that with others companies from that country have produced the LGBTQ and Opioid crisis. Psychedelics are also instrumental as a gate to the realm of aliens, demons, monsters, etc. Couple this with an OpenAI executive stating: “The truth of this is, we're building portals from which we're genuinely summoning aliens…” It appears that the Old Gods are being invoked and and aligned with the Old Testament tribal god of the Israelites.*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore China's burgeoning role in the synthetic biology sector, as outlined in a recent article discussing China's strategic focus on biotechnology within its latest five-year plan. This strategy identifies biomanufacturing, particularly synthetic biology and genetic engineering, as pivotal for China's emerging bioeconomy. The nation's approach frames biology as a transformative industrial platform poised to reshape pharmaceuticals, materials science, agriculture, and energy industries. Central to this transformation is DNA synthesis, which allows for the design and manufacture of genetic sequences. As China rapidly expands its synthetic biology capabilities, questions arise about its potential to become an innovation powerhouse, the competitiveness of Chinese firms in DNA synthesis, and geopolitical factors affecting international cooperation and supply chains. Insights from industry leaders highlight China's unique industrialization strengths. The country excels in rapidly scaling technologies due to its ability to mobilize capital, infrastructure, and manufacturing swiftly—a capability that surpasses Europe and the U.S. This aligns with China's national biomanufacturing strategy aimed at developing vast production systems across pharmaceuticals and industrial biotechnology. Beyond sheer manufacturing capacity, China is constructing a comprehensive ecosystem to bolster advanced biotechnology. The nation's development of clinical infrastructure and pharmaceutical manufacturing is noteworthy. China is actively exploring personalized therapies and building regulatory pathways for advanced treatments, signaling a potential shift in global biotech dynamics. Domestically, Chinese companies are developing technology platforms to reduce dependence on imported equipment and Western supply chains. The competitive landscape in DNA synthesis is evolving beyond traditional commodity-versus-innovation narratives, as both Chinese and Western companies pursue similar technological advancements. However, geopolitical tensions complicate collaborations between Chinese and Western firms. Export controls highlight the growing barriers to cooperation. Despite price competitiveness from Chinese DNA synthesis providers, concerns over data security and regulatory risks are prompting some Western buyers to favor suppliers from Europe or the US. Shifting gears to regulatory matters, recent developments highlight a dynamic industry characterized by scientific advancements, regulatory shifts, legal battles, and strategic corporate maneuvers. Central to these is the call for enhanced transparency and evidence standards in the FDA's accelerated approval pathway. Strengthening evidence requirements aims to ensure that drugs approved under this pathway are supported by robust scientific data, ultimately safeguarding patient health and maintaining public trust in regulatory institutions. A landmark financial event has unfolded with Kailera Therapeutics' record-breaking IPO, raising $625 million to bolster its obesity treatment pipeline. This significant capital inflow not only sets a new benchmark for biotech IPOs but also underscores burgeoning interest in addressing obesity—an area with substantial unmet medical needs. In legal arenas, Teva Pharmaceuticals scored a victory as an appeals court revived a $177 million verdict against Eli Lilly concerning patent disputes over migraine medications. Additionally, Viatris and Teva have initiated recalls due to issues with drug dissolution and raw material approvals. The appointment of Dr. Erica Schwartz as the potential Director of the CDC marks another pivotal moment. Her leadership could steer the CDC towards more effective public health responses. On a broader industry scale, there is anSupport the show

Moderator: Marian Hurducaș.Co-host: Radu Puchiu, expert e-guvernare.Invitat: Daniel Tămaș, antreprenor IT, cel care a demarat demoanaf.ro

In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh spoke with Kashif Sadiq, founder and CEO of DenovAI Biotech, a company that believes humanity is on the cusp of a protein design revolution that stands to transform both human health and the world around us. Sadiq discusses the company's springboard from AION Labs - with a first-of-its-kind alliance of AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and Amazon Web Services, powered by BioMed X with the support of the Israeli Government. He also explores harnessing the power of artificial intelligence and computational molecular biophysics, developing foundational technology platforms that can design proteins de novo, and describes the trends and insights from the conference itself this year.

In this episode we speak with Mike Warden -the 51 year old adventure runner who recently set the record for fastest 50k on Seven Continents in Seven Consecutive Days!  He’s also planning to row across the Atlantic Ocean. Links Mentioned in This Episode Run Coaching. Work with an expert MTA Running Coach. Air Doctor Pro air purifier: use promo code MTA to get UP TO $300 off today! AirDoctor comes with a 30-day money back guarantee, plus a 3-year warranty—an $84 value, free!   IQBAR brain and body-boosting bars, hydration mixes, and mushroom coffees. Their Ultimate Sampler Pack includes all three! Get 20% off plus FREE shipping. Just text “MTA” to 64000. Michael Wardian short bio: Husband, Father, Ship Broker, Sponsored Elite Runner (sponsored by Teva), Speaker, Running Coach, Chess Player, Pickleballer, Beekeeper, Guinness World Record Holder, Race Director, Dog Runner. Wardian has set 25 Fastest Known Time running records in five countries and he races frequently at multiple distances. He has won national championships at 50k, 50 miles, and 100k. He has completed the 7 Continents Challenge three times, set a FKT on the AT, and has run across the US.

In this episode of BRAVE COMMERCE, Rachel Tipograph and Sarah Hofstetter sit down with Dipesh Patel, Senior Director, Digital Transformation & Ecommerce, Global OTC at Teva Pharmaceuticals, to discuss what it takes to drive transformation in a category where trust, accuracy, and regulation shape the pace of change. Dipesh shares how his background in mathematics and early experience in retail influence his approach to problem-solving, ambiguity, and digital transformation.They also explore Dipesh's move from Unilever to Teva, including the difference between operating in a mature consumer goods environment versus building capabilities in OTC. The conversation also dives into AI's role in content creation, why speed alone isn't enough in healthcare, and how brands can use stronger systems and guardrails to scale content while maintaining control.Key takeawaysAI can scale content production, but strong guardrails and human oversight remain essential.In healthcare and OTC, brands must balance digital speed with trust and regulatory rigor.Building digital capabilities from scratch requires a different mindset than optimizing mature systems. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that highlight the intricate interplay of scientific innovation, regulatory dynamics, and strategic maneuvers shaping the industry.Starting with Moderna, the company has reached a pivotal resolution in a long-standing patent dispute involving its mRNA-based COVID-19 vaccine, Spikevax. This settlement involves a hefty $950 million payout to Genevant Sciences and Arbutus Biopharma, resolving claims of patent infringements. This agreement underscores the complex nature of intellectual property in the rapidly evolving mRNA landscape. Securing patent rights is crucial as new vaccines and therapies are developed, and this resolution not only clears a legal hurdle for Moderna but also exemplifies the industry trend towards resolving such disputes to foster continuous innovation.Sanofi has embarked on a significant strategic move by entering a $1.53 billion global licensing deal with Sino Biopharmaceutical. This agreement secures rights to a first-in-class JAK/ROCK inhibitor, which shows promise in treating hematological and immunological conditions. Such collaborations reflect the increasing focus on innovative therapies that target complex biological pathways, highlighting how companies are seeking unique assets to bolster their competitive edge.Regulatory scrutiny continues to be a formidable theme in the industry. The FDA has intensified its oversight on compounded GLP-1 drugs, issuing 30 warning letters to telehealth companies marketing unauthorized versions. This action highlights the agency's commitment to ensuring drug safety and efficacy while emphasizing the challenges companies face in navigating regulatory landscapes for compounded medications. Additionally, Novo Nordisk has been cautioned by the FDA regarding advertising practices for GLP-1 receptor agonists, illustrating the ongoing regulatory focus on pharmaceutical marketing strategies and compliance standards.Meanwhile, Bayer is experiencing a period of resilience in its pharmaceutical division, driven largely by its cancer drug Nubeqa and cardiovascular agent Kerendia. Despite these successes, Bayer faces challenges as revenues from older drugs like Xarelto and Eylea decline. This scenario reflects a broader industry challenge where companies must innovate while managing mature product lines facing generic competition.Teva Pharmaceuticals is making strategic strides by securing a $400 million deal with Blackstone to develop an anti-TL1A antibody for inflammatory bowel disease (IBD), in partnership with Sanofi. This investment highlights continued interest in autoimmune and inflammatory conditions as lucrative targets for novel therapies. Financial partnerships like Teva's substantial agreement with Blackstone illustrate how such collaborations can support sustained R&D efforts in chronic disease management.Technological integration into healthcare is expanding rapidly, with Nvidia collaborating with Droplet Biosciences to explore AI applications in medtech and cancer research. These partnerships illustrate an industry shift towards leveraging artificial intelligence to enhance diagnostic capabilities and accelerate research efforts. Moreover, collaborations leveraging AI/ML technologies across drug discovery pipelines are gaining traction; Earendil Labs partnering with WuXi XDC exemplifies this trend alongside Merck & Co.'s multi-year AI oncology data deal with Tempus—enhancing precision medicine capabilities while expediting therapeutic discoveries.In terms of funding new therapeutic areas, ARPA-H has announced a $158 million initiative aimed at developing medicines targeting the lymphatic system. This marks an exploration into less charted territories within physiological research that could yield transforSupport the show

Sunt patru ani de când, într-o dimineață, ne-am trezit brusc într-o altă lume. De când am aflat, stupefiați, că războiul poate fi o realitate imediată. Chiar în Europa noastră, în care pacea părea inslatată pentru totdeauna. Pentru noi, cei din redacția RFI România, lumea în care am intrat după 24 februarie 2022 a însemnat și vecinătatea imediată cu noii noștri colegi, de la redacția în limba ucraineană. Un efort major, într-un timp scurt, al RFI și al companiei-mamă France Medias Monde, de înființare a redacției ucrainene la bucurești, pentru a sprijini țara sfâșiată de război. Ucrainenii, sub presiunea invaziei rusești, au nevoie de multe - de echipamente militare, de adăposturi, de alimente, de energie și căldură. Dar au nevoie și de informație curată, într-un război în care agresorul lucrează din plin și pe frontul dezinformării. Așa a apărut redacția ucraineană de la București, care a început să lucreze efectiv în anul următor al declanșării invaziei. De atunci,  Bucureștiul a devenit un hub regional al RFI, un avanpost al luptei împotriva narațiunilor false ale Rusiei. Iar jurnaliștii ucraineni – cu precădere jurnalistele, din motive ușor de înțeles, date fiind restricțiile legate de părăsirea țării – au devenit parte din echipa noastră. Fiecare, cu propria poveste a plecării din Ucraina, cu traumele zilelor de război, ale refugiului, cu soți, iubiți, membri ai familiei prieteni, aflați pe front. Cu cei dragi rămași în locuri pericolase. Cu viețile și carierele profesionale bulversate de război. Lucrăm împreună în fiecare zi, ne sprijinim, schimbăm informații. Prin intermediul lor suntem și noi, redacția în limba română, cu un pas mai aproape de realitatea sumbră a războiului. Și tot colegii ucraineni mi-au oferit, fără să vrea, o lecție despre ce înseamnă cu adevărat războiul. Ziua aceea din miez de vară nu o pot uita. Discutam, într-un seminar, despre România, țara lor de adopție. Erau curioși să afle despre viața politică, societate, istorie, obiceiuri și mentalități. Și, în timpul pasionantei discuții, o escadrilă militară a vâjâit aproape de ferestele birourilor noastre, cu un efect imediat asupra colegilor ucraineni. Le-am văzut privirile speriate, i-am văzut tresărind, gata să-și caute un adpost. I-am liniștit imediat – sunt doar pregătiri pentru Ziua Aviației. ”Nu vă faceți griji, sunteți în siguranță”. Și în acele clipe de confuzie am înțeles ce înseamnă cu adevărat traumele războiului. Sperăm că războiul se va termina cât mai repede. Și colegii noștri ucraineni vor începe să relateze nu despre drone, despre morți, răniți, crize umanitare. Ci despre reconstrucția țării lor și procesul de aderare la Uniunea Europeană.

Welcome to the Hyperspace Heroes Podcast, where 3 Gen 1 Star Wars fans are just trying to make their way in the Star Wars podcast universe. HHP EP 160 Brown 85 (Teva), Adelphi Rangers on IG, joins us and we talk about the Mando & Grogu movie commercial during the “big game” and we talk the latest toy announcements supporting that movie. We wrap up with Collection Corner and SW Dad Joke of the Week.Hyperspace Heroes Podcast does weekly livestreams on Thursday nights at 8pm eastern. Audio versions are posted on all the pod catchers the following Mondays. You can find all of our links for livestreams, podcasts and social media athttps://beacons.ai/brownsquadronIntro/Outro Music: Strange Signal (Instrumental) HoliznaCCO/ Licensed under CCO 1.0 Universal License https://creativecommons.org/publicdomain/zero/1.0/legalcodeSource: Free Music Archive https://freemusicarchive.org/music/holiznacc0/straight-to-vhs/strange-signal/Support HoliznaCCO via hisPatreon: https://www.patreon.com/HoliznaBandcamp: https://holiznaroyaltyfree.bandcamp.com/Buy Me A Coffee: https://www.buymeacoffee.com/HoliznaVoice Over Work in Intro/Outro Performed by Milz Bowden & Henri GageYou can find Milz & Henri at https://youtube.com/@video4humans

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a whirlwind of activity in the industry, where scientific breakthroughs, regulatory shifts, and strategic collaborations are all reshaping the future of healthcare.Let's start with a look at the ongoing efforts by the Trump administration to negotiate Medicare drug prices under the Inflation Reduction Act. This initiative is set to impact 15 high-profile drugs, marking a significant push towards more stringent pricing regulations. The aim is to make medications more affordable for patients, but this move could also compel pharmaceutical companies to rethink their pricing strategies and revenue models. Such regulatory changes underscore a broader trend toward cost containment in healthcare, a critical issue as drug prices continue to be a major concern for policymakers and consumers alike. Additionally, proposed changes to Medicare Advantage rates by the Trump administration could lead to benefit cuts or market exits by insurers, highlighting ongoing uncertainties in healthcare financing that could significantly impact patient access to care.In the realm of oncology, Johnson & Johnson has achieved another milestone with its Darzalex Faspro. This drug has received FDA approval for an expanded indication in treating newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplants. This approval is not just a regulatory win; it reflects the growing importance of combination therapies in enhancing treatment outcomes for complex diseases like multiple myeloma. The shift towards combination regimens is a notable trend in oncology, aiming to maximize therapeutic efficacy and improve patient survival rates.Meanwhile, Teva Pharmaceuticals is bracing for a potential slowdown come 2026 after a period of growth. This projection highlights the inherent volatility in the pharmaceutical market, where external factors such as regulatory changes and competitive pressures can swiftly alter financial trajectories. Companies like Teva must remain agile and adaptable to navigate these unpredictable waters.On the innovation front, Cellares has secured $257 million in a Series D funding round aimed at expanding its cell therapy contract manufacturing operations globally. This significant investment underscores an increasing demand for advanced therapeutic manufacturing capabilities, reflecting the industry's pivot towards personalized medicine and cell-based therapies. As the landscape of medicine shifts towards more individualized approaches, companies like Cellares are positioning themselves at the forefront of this transformative trend.Novo Nordisk is actively exploring new growth avenues, with its business development head engaging in numerous strategic meetings at the J.P. Morgan Healthcare Conference. This proactive approach illustrates how critical partnerships and acquisitions are becoming for pharmaceutical companies looking to maintain a competitive edge and drive innovation forward. Novo Nordisk's pursuit of Metsera aligns with broader industry trends where strategic acquisitions are leveraged to bolster pipelines with innovative therapies.Pfizer continues to dominate the vaccine production arena despite challenging market conditions that have seen competitors like Sanofi face setbacks. This leadership can be attributed to Pfizer's robust product pipeline and strong relationships with healthcare providers, highlighting how trust and reliability remain crucial components of success in this field.In gene therapy news, Eli Lilly has forged a $1.1 billion agreement with Seamless Therapeutics aimed at developing gene-editing medications for hearing loss. This collaboration is indicative of gene therapy's expanding scope, offering hope for addressing previously untreatable conditions Support the show

With this year’s iteration of the J.P. Morgan Healthcare Conference in the rearview mirror, the biopharma industry has officially closed the door on 2025 as it heads into what is sure to be another eventful year. In this week’s episode of "The Top Line," Fierce Pharma's Zoey Becker sits down with Angus Liu and Fierce Biotech's Gabrielle Masson to unpack the key topics and trends that stood out at this year's conference in San Francisco. The conversation offers an early look at the themes and questions that could shape the year ahead. To learn more about the topics in this episode: All the meetings, none of the megadeals: Is JPM's purpose evolving? JPM26: What’s in a biopharma? CEO says Teva has the goods JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears See omnystudio.com/listener for privacy information.

Reese is on assignment in Arizona to check out the course for her upcoming race, Black Canyon 100k. She gives the details on her trip, her training, and even a GOAT sighting on the trail. Taylor and Reese then try to sort out the whole "gravel running" conversation and talk about if it's a worthy category to get excited about.Guest: Teva athlete Michael Wardian returns to the show to catch up with Taylor. They mull over a bunch of topics ranging from his busier-than-ever schedule, Burrito League, sandals, and his upcoming world record attempt of 7x50k in 7 days on 7 continents.SUPPORT OUR SPONSORS!LMNTThe Lemonade Salt has returned for good, so make sure you grab the greatest flavor on the planet for all your trail running needs. You'll be getting 1,000 mg of sodium plus other key electrolytes that will restore balance to your life after any hard effort. You'll also get an 8-count LMNT Sample Pack with any purchase, so don't miss out: http://drinklmnt.com/dirtdivision

v dnešnom podcaste si vypočujete aj: - Bol by Trump schopný sfalšovať voľby? - Ako sa má Európa k USA a ich prezidentovi správať a čo by sme mu mali v Davose povedať. - Čo dokázal a nedokázal Donald Trump za rok svojho prezidentovania

"I think brands are looking for people to represent all different aspects of running." Michael Wardian is a TEVA sponsored professional athlete. In this episode, Michael chats with Luis about where to run in Washington DC, relationship with TEVA, history of TEVA, TEVA's new trail shoes, advise on being a brand ambassador, the DMV Chipotle Burrito League, and running prizes for different segments. Support Road Dog Podcast by: 1. Joining the Patreon Community: https://www.patreon.com/roaddogpodcast 2. Subscribe to the podcast on whatever platform you listen on. GO SLEEVES: https://gokinesiologysleeves.com HAMMER NUTRITION show code: Roaddoghn20 Listeners get a special 15% off at https://www.hammernutrition.com DRYMAX show code: Roaddog2020  Listeners get a special 15% off at https://www.drymaxsports.com/products/ LUNA SANDALS "Whether I'm hitting the trails or just hanging out, LUNA Sandals are my favorite. They're designed by Barefoot Ted of Born to Run and made for every adventure—ultra running, hiking, or just kicking back. Its minimalist footwear that's good for your feet!" Check them out and get 15% off at lunasandals.com/allwedoisrun. PARADISE SOAP: https://www.paradiseroadsoapco.com/ TEVA: https://www.teva.com/ Allwedoisrun.com Michael Wardian Contact Info: TEVA: https://www.teva.com/ Strava: strava.app.link/9ISncFzzPZb Instagram: @michaelwardian Bureau Of Adventure: https://www.teva.com/bureau-of-adventure.html Luis Escobar (Host) Contact: luis@roaddogpodcast.com Luis Instagram Kevin Lyons (Producer) Contact: kevin@roaddogpodcast.com yesandvideo.com Music: Slow Burn by Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/ Original RDP Photo: Photography by Kaori Peters kaoriphoto.com Road Dog Podcast Adventure with Luis Escobar www.roaddogpodcast.com  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic phase shaping the industry, marked by scientific advancements, regulatory changes, and strategic shifts within major companies.Teva Pharmaceuticals is making significant strides under the leadership of CEO Richard Francis. The company is transitioning from its traditional focus on generic drugs to a more innovative biopharmaceutical approach. This strategic pivot aims to position Teva alongside industry giants in the biopharma sector, highlighting the increasing importance of innovation over generics in today's competitive landscape.Similarly, Fujifilm is enhancing its competitive edge by capitalizing on its biologics capacity. Rather than pursuing large mergers and acquisitions, Fujifilm is focusing on internal growth, underscoring a broader industry trend where companies are investing in organic growth and technological enhancements to maintain their market positions. This shift reflects a growing recognition of the value of leveraging unique facility designs and capabilities to boost production and efficiency.In regulatory news, the U.S. Food and Drug Administration (FDA) has mandated that pharmaceutical companies like Sanofi, GSK, AstraZeneca, and CSL include warnings about febrile seizures on flu vaccine labels. While these seizures are typically brief and harmless, transparent communication is crucial to maintain patient trust in vaccination programs. This regulatory update exemplifies the FDA's proactive efforts to enhance drug safety communications and address potential adverse effects associated with vaccines.The FDA has also issued untitled letters to Beone and ImmunityBio for promotional materials that potentially violated advertising guidelines. This action underscores the agency's vigilance in ensuring pharmaceutical marketing practices meet required standards of accuracy and transparency.Meanwhile, former Emergent BioSolutions CEO Robert Kramer faces insider trading allegations related to the sale of company shares before public disclosure of contamination issues at a production facility. This legal action brings to light ongoing scrutiny within the industry regarding corporate governance and ethical practices.In terms of advertising spending, AbbVie's Skyrizi topped annual TV ad spending charts for pharmaceuticals, closely followed by J&J's Tremfya. This highlights the continued emphasis on direct-to-consumer advertising as companies compete for market share in therapeutic areas.Internationally, companies like AbbVie are making strategic moves into emerging therapeutic spaces such as bispecific antibodies. AbbVie's recent deal to enter the PD-1xVEGF bispecific space signifies a growing interest in novel therapeutic modalities that offer potential breakthroughs in cancer treatment.At the policy level, former President Donald Trump announced "The Great Healthcare Plan," targeting insurance industry reforms and drug pricing. Although specifics remain sparse, this initiative reflects ongoing political discourse around healthcare affordability—a critical issue shaping industry strategies and public expectations.Turning our attention to Vedanta Biosciences, the company is reallocating resources toward its lead live bacteria cocktail program by significantly reducing its workforce. This move highlights growing interest in microbiome-based therapies as a novel approach to treating diseases by modulating gut microbiota. Vedanta's focus could have substantial implications for future therapeutic options, particularly in immune-related conditions.At the J.P. Morgan Healthcare Conference (JPM26), Chugai Pharmaceutical emphasized enhancing its recognition in the U.S. biopharma sector through new scientific avenues. This strategy underscores the importance of innovation and collaboration for Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant events and trends reshaping the industry landscape as we approach 2026. The pharmaceutical and biotech sectors are navigating a transformative period marked by scientific advancements, evolving regulatory frameworks, and strategic partnerships.Starting with a shift towards bolstering drug pipelines, mergers and acquisitions (M&A) have gained momentum. In 2025, this trend was largely fueled by impending patent expirations and an optimistic investment climate within biotech. Pharmaceutical companies are strategically pursuing these opportunities to enhance their innovation capabilities, positioning themselves effectively against competitive pressures. AbbVie's recent $5.6 billion agreement with RemeGen is a testament to this strategy. By entering the PD-1xVEGF bispecific antibody market, AbbVie aims to establish a foothold in a promising area of cancer therapeutics. This investment highlights the growing interest in bispecific antibodies due to their dual-targeting potential, offering enhanced treatment efficacy by simultaneously addressing two cancer pathways.Meanwhile, Eli Lilly's collaboration with Nvidia demonstrates the increasing integration of artificial intelligence (AI) in drug discovery. Their $1 billion co-innovation lab investment aims to harness AI technologies to accelerate new therapy development and refine precision medicine approaches. This partnership exemplifies the transformative potential of AI in optimizing research productivity across the industry.On the regulatory front, Atara Biotherapeutics and Pierre Fabre Pharmaceuticals faced challenges with their EBVallo product. The FDA's repeated rejection of this product underscores the intricate regulatory landscape biopharmaceutical companies must navigate. This situation highlights the necessity for clear communication between industry players and regulatory bodies to ensure innovative therapies reach patients needing them most.In clinical development, Bristol Myers Squibb's Camzyos is set for expansion following successful trials in adolescent patients with cardiomyopathy. This advancement signifies a crucial step towards making advanced therapies available to broader patient demographics, potentially transforming cardiology care.Investment in infrastructure remains a priority as AbbVie announces a $175 million development of a new drug-device plant in Arizona. This move aligns with their broader commitment to invest $10 billion into U.S. operations by 2035, underlining the importance of enhancing manufacturing capabilities and securing supply chains in a globalized market.Additionally, Teva's financial maneuvering with Royalty Pharma illustrates how biopharma firms support clinical advancements through strategic funding partnerships. By securing up to $500 million for its vitiligo drug development, Teva highlights the critical role of financial collaborations in advancing therapeutic innovations.All these developments occur amid concerns about potential governmental threats to scientific integrity within the U.S. biotech industry. Flagship Pioneering's CEO warns that policy changes could undermine fundamental scientific principles, potentially hindering innovation and progress within the sector.As we transition into 2026, there's renewed optimism within biopharma driven by increased investor interest and robust R&D initiatives. This resurgence is expected to be a focal point at upcoming conferences like JPM26, where discussions on policy and political influences on drug pricing will be pivotal.In oncology, Merck & Co.'s rumored acquisition of Revolution Medicines could signal an aggressive expansion of its oncology portfolio. This potential transaction would underscore Merck's strategic focus on small moleSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show

“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we’re in a unique position where we can stay really hyper-focused on what we’re doing. I’m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they’re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva’s doing right.” In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.See omnystudio.com/listener for privacy information.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

What happens when you stop waiting for permission and start chasing wild, audacious goals? That's exactly what we unpack in this powerhouse episode with Mike Wardian—elite endurance athlete, record-setting runner, and all-around inspiration. From running across the United States to setting a fastest known time (FKT) on the Appalachian Trail for his age group, Mike shares the mindset behind tackling the unimaginable. But this conversation goes beyond races and records. Mike opens up about what fuels his drive, how he builds resilience through repetition, and how he balances his career, family, and love for adventure. Whether you're prepping for your first 10K or dreaming of rowing solo across the Atlantic (yep, that's on his calendar too), there's something here for everyone chasing big goals.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several groundbreaking advancements and strategic shifts in the industry that promise to reshape the landscape of patient care and therapeutic innovations.The U.S. Food and Drug Administration has introduced a novel regulatory pathway aimed at expediting the approval process for custom gene-editing therapies. Articulated by FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., this new approach is set to revolutionize personalized medicine, particularly for genetic disorders where tailored interventions are crucial. Gene editing technologies, like CRISPR-Cas9, have opened unprecedented avenues for addressing genetic conditions directly at their source. However, the regulatory framework has struggled to keep pace with these advances, often hampering innovation with lengthy and complex approval processes.This proposed pathway seeks to streamline these requirements by adopting a risk-based assessment model that considers the unique properties of gene-editing therapies. Unlike traditional drugs, which follow a uniform clinical trial path, gene-editing treatments require a more nuanced regulatory approach due to their precision and potential off-target effects. The framework emphasizes adaptive trial designs—allowing for modifications based on interim results—and integrates real-world data to create a dynamic regulatory process. This not only promises faster development times but also fosters innovation by making it easier for companies to bring cutting-edge therapies to market.The implications are far-reaching. For researchers and biotech firms, this represents a chance to reduce time-to-market significantly while maintaining high safety standards. It also sets a precedent for future regulatory models that prioritize patient-centric approaches, acknowledging the diverse genetic landscapes of individuals with rare diseases. On a broader scale, this shift underscores the increasing recognition of personalized medicine's potential to transform healthcare delivery.In parallel developments, Gilead Sciences has achieved positive phase 3 results for its single-tablet regimen combining bictegravir and lenacapavir for HIV treatment. This milestone offers hope for simplifying treatment protocols for patients currently on multi-tablet regimens, potentially enhancing adherence and improving health outcomes. Gilead's preparation for regulatory filings marks an essential step forward in their therapeutic portfolio.Turning to cancer treatment advancements, Kyowa Kirin's collaboration with Kura Oncology has led to FDA approval for an oral medication targeting a subset of acute myeloid leukemia patients. This approval highlights the power of strategic partnerships in expediting the development of targeted cancer therapies and brings new hope to patients with limited treatment options.Meanwhile, several pharmaceutical companies, including Fresenius, Sun Pharma, and Teva, have been involved in product recalls ranging from hospital drugs to antibiotics and ADHD medications. These recalls underscore ongoing challenges in maintaining drug safety standards and emphasize the need for rigorous quality control measures across the industry.Zealand Pharma has opted to pause development of its dual GLP-1/GLP-2 agonist, dapiglutide, due to an increasingly crowded metabolic disorder treatment landscape. By reallocating resources towards programs with greater clinical differentiation potential, Zealand reflects broader industry trends prioritizing investments in areas with clearer paths to market success.In malaria treatment advances, Novartis has achieved significant progress with its next-generation drug 'Ganlum,Support the show

Shares of generics drugmaker Teva Pharma jumping double digits after earnings. Its CEO breaks down the impact of tariffs and price negotiations on margins. Then an inside look at Aramco's AI strategy, live from its headquarters in Saudi Arabia. Plus, the Supreme Court hears challenges against the Trump administration's tariff policies. A live report from outside the court room. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

While many celebrate the bombing of boats in the Caribbean, that may or may not be affiliated with drug trafficking, others condemn it for political reasons.  What both arguments failed to realize is that major banking institutions across the United States, and across the world, are the biggest drug money laundering institutions. What is happening in the Caribbean is more akin to smoke and mirrors. From Chinese cartels to Mexican cartels, banks in Europe in the United States, launder much of the money. For Iran-Contra alone, we learned that the US government will illegally moves drugs, guns, and humans across borders for purposes that circumvent Congress. Threats of using the US military in Venezuela strike of decades of regime change operations in that part of the world for natural resources and to the benefit of multinational corporations. Venezuela has virtually nothing to do with the fentanyl drug trade, and very little to do even with the cocaine drug trade. Mexico is the central source of fentanyl distribution, largely from China, and yet Venezuela is the target of the US military. Companies like Teva pharmaceuticals, located in Israel, should be at the forefront of these discussions, too, considering that it is one of the primary contributors to the opioid crisis in the United States. But we leave the banks that launder the money out of the equation, just as we leave pharmaceutical companies that contribute to drug problems out of the equation, just as we neglect to address cultural issues that contribute to drug disease plagugin our country. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKWEBSITEBuyMe-CoffeePaypal: rdgable1991@gmail.comCashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

This was a straightforward Monday crossword, as Monday crosswords tend to be, and an enjoyable crossword, as all NYTimes crosswords edited by Will Shortz are destined to be. We were glad to spot the HIDEYHOLE at 33D; marvel at ICEDANCERS not too far removed at 28D; and delight at 40A, "Sure is", YEP (which, coincidentally, is our answer to the question, was this a great crossword?).We also have our JAMCOTWA™️ (Jean And Mike Crossword Of The Week Award) pronouncement, and some awesome listener mail, leading to an equally awesome discussion of a Lone Ranger catch phrase.Show note imagery: TEVA, for all your hiking sandal needsShow note links: What exactly is the Lone Ranger saying at the start of each episode, anyway?We love feedback! Send us a text...Contact Info:We love listener mail! Drop us a line, crosswordpodcast@icloud.com.Also, we're on FaceBook, so feel free to drop by there and strike up a conversation!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

How did a couple of California surfers turn a flip-flop side hustle into one of the best-performing stocks of the past 20 years? In this two-part special, Skippy & Doogles unpack the wild origin story of Deckers Outdoor—makers of Teva, UGG, Hoka, and more.This is Part 1, covering 1973–2003: a journey of grit, sandals, lawsuits, and ugly boots that somehow took over the world.Join the Skippy and Doogles fan club. You can also get more details about the show at skippydoogles.com, show notes on our Substack, and send comments or questions to skippydoogles@gmail.com.

In this engaging conversation, Tommie Runz discusses the evolution of Teva as a brand in the outdoor footwear industry, highlighting its commitment to innovation and athlete feedback. The discussion features insights from ultra runner Mike Wardian and Henry, Teva's design head, focusing on the unique challenges and experiences of trail running. The conversation also touches on personal stories, the importance of community in outdoor activities, and the spirit of adventure that drives both the athletes and the brand.